Sign Up to like & get
recommendations!
1
Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2797
Abstract: Comparative effectiveness evaluation of newer P2Y12 inhibitors (prasugrel and ticagrelor) compared with clopidogrel after acute coronary syndrome (ACS) is limited in real‐world US populations. The objective of this study was to evaluate cardiovascular events based…
read more here.
Keywords:
ticagrelor;
prasugrel clopidogrel;
clopidogrel;
comparative effectiveness ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2018.01.027
Abstract: Ticagrelor is a nonthienopyridine direct and reversible P2Y12 platelet receptor antagonist, and unlike prasugrel or clopidogrel inhibits, at least partially, the sodium-independent equilibrative nucleoside transporter 1 [(1)][1]. This ticagrelor-mediated off-target effect has potential to improve
read more here.
Keywords:
prasugrel;
clopidogrel steady;
prasugrel clopidogrel;
ticagrelor prasugrel ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Journal of Atherosclerosis and Thrombosis"
DOI: 10.5551/jat.63473
Abstract: Aim: To examine the efficacy and safety of prasugrel vs clopidogrel in thrombotic stroke patients at risk of ischemic stroke. Methods: This multicenter, active-controlled, randomized, double-blind, double-dummy, parallel group study enrolled thrombotic stroke patients aged…
read more here.
Keywords:
efficacy;
prasugrel;
ischemic stroke;
prasugrel clopidogrel ... See more keywords